Liver - Stocks of the Day

Stocks of the Day

Sign In / Sign Up

Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Home
Latest News
Stock Screener
AI Signals
News Archive
Membership
About
- About
- FAQ
- Blog
- Contact Us

Register Free
Sign in

Search mobile

Topic :

Liver

NASDAQ, PRTC

#Investor Conference #Liver

Vedanta Biosciences to Present at Upcoming Investor Conferences

January 26, 2023
07:00

EST

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vedanta Biosciences, a clinical-stage biopharmaceutical company pioneering the development of oral therapies based on defined bacterial consortia, today announced that members of its executive team will participate at the following investor conferences: William Blair Biotech Private Company Conference Date: Monday, January 30, 2023 Virtual Fireside chat time:

No Comments

GALT, NASDAQ

#Liver

Galectin Therapeutics contribution to improve histology interpretation of cirrhotic liver biopsies with Machine Learning published in prominent Gastroenterology Journal

January 24, 2023
08:00

EST

NORCROSS, Ga., Jan. 24, 2023 (GLOBE NEWSWIRE) — Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, today announced that the scientific paper, “Machine Learning Liver Histology Scores Correlate With Portal Hypertension Assessments In Nonalcoholic Steatohepatitis Cirrhosis,” was published in Alimentary Pharmacology and Therapeutics, a prominent

No Comments

AMEX, CANF

#Liver #Patent #Trending News

Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed

January 24, 2023
07:00

EST

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases, today announced that its anti-cancer drug Namodenoson significantly inhibits the growth of pancreatic carcinoma as a stand-alone treatment. In combination

No Comments

CBAY, NASDAQ

#Liver #Shares Pricing #Trending News #Warrants

CymaBay Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

January 24, 2023
07:00

EST

NEWARK, Calif., Jan. 24, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced the pricing of its previously announced underwritten public offering of common stock and pre-funded warrants.

No Comments

CBAY, NASDAQ

#Liver #Shares Release #Trending News #Warrants

CymaBay Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

January 23, 2023
16:11

EST

NEWARK, Calif., Jan. 23, 2023 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (Nasdaq: CBAY), a clinical-stage biopharmaceutical company focused on developing therapies for liver and other chronic diseases with high unmet medical need, today announced that it has commenced an underwritten public offering of its common stock and pre-funded warrants.

No Comments

NASDAQ, NSTG

#Liver #Trending News

NanoString Releases Single Cell Spatial Transcriptomics Dataset Highlighting Data Quality of CosMx Spatial Molecular Imager

January 19, 2023
06:00

EST

SEATTLE–(BUSINESS WIRE)–NanoString Technologies, Inc. (NASDAQ: NSTG), a leading provider of life science tools for discovery and translational research, today announced a public release of new data generated by the CosMx™ Spatial Molecular Imager (SMI). This data was generated from formalin-fixed paraffin-embedded (FFPE) human liver samples and showcases the best-in-class

No Comments

OTC, RHHBY

#Liver #Phase 3 #Positive Clinical Trial Results

Genentech’s Tecentriq Plus Avastin Is the First Treatment Combination to Reduce the Risk of Cancer Returning in People With Certain Types of Early-Stage Liver Cancer in a Phase III Trial

January 19, 2023
01:00

EST

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that the Phase III IMbrave050 study met its primary endpoint of recurrence-free survival (RFS) at the prespecified interim analysis. The study is evaluating Tecentriq® (atezolizumab) in combination with Avastin® (bevacizumab) as

No Comments

AMEX, CANF

#Liver #Private Placement #Trending News

Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement

January 11, 2023
09:04

EST

PETACH TIKVA, Israel–(BUSINESS WIRE)–Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address inflammatory, cancer and liver diseases (“Can-Fite” or the “Company”), today announced that it has entered into definitive agreements for the purchase and sale of 1,000,000

No Comments

HEPA, NASDAQ

#Liver #Trending News

Presentation of Preclinical Study Highlighting Anti-Cancer Activity of Rencofilstat in Combination with Proteosome Inhibitors

January 10, 2023
16:15

EST

EDISON, N.J., Jan. 10, 2023 (GLOBE NEWSWIRE) — Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”), hepatocellular carcinoma (“HCC”), and other chronic liver diseases, announced that its research collaborator, Carlos Perez-Stable, PhD, from

No Comments

CYTO, NASDAQ

#Liver #Trending News #Upcoming Presentation

Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th

January 10, 2023
08:47

EST

Hamilton, Bermuda, Jan. 10, 2023 (GLOBE NEWSWIRE) — Company COO Dr. Pañeda will discuss SemaPhoreTM platform’s functionality with mRNA, and: Peptide-based platform for extrahepatic delivery The extrahepatic success of, and prospects for, SemaPhore vs other liver-restricted delivery methods Altamira Therapeutics Ltd. (NASDAQ:CYTO), a company dedicated to developing therapeutics that

No Comments

< Page1 Page2 Page3 … Page62 >

Trending News

Helbiz Provides Transparency on Filed Proxy Statement

01/27/2023

CNEY Announces Proposed Underwritten Public Offering of Securities

01/27/2023

CNEY Reports Its Audited Financial Results for Fiscal Year 2022

01/27/2023

Hannon Armstrong Announces 2022 Dividend Income Tax Treatment

01/27/2023

DecisionPoint Systems Launches MobileConductor Express

01/27/2023

Most read news

STEER Announces a Proposed Transaction for an $18 Million Direct Investment Involving its Digital Restaurant Supply Business (B2B Marketplace)

01/23/2023

Ra Medical Systems Announces the Presentation of Clinical Data at the European Heart Rhythm Association Congress

01/23/2023

Sona Nanotech to Acquire Cancer Therapy Developer Siva Therapeutics

01/26/2023

© 2022 stocksoftheday.

Stocks of the Day does not provide investment advice. All rights reserved.

Tools

Predictions
Stock Screener
News Archive
News Feed
News Tags
Tickers
Trending Tickers
News Sentiments
Holidays & Trading Hours

Learn

FAQ
Guides
Infographics
Affiliate Program FAQ

Account

Sign In
Register
Email Preferences
Membership Option

Company

About
Contact Us
Careers
Blog
Privacy Policy
Terms of Use
Sitemap

Partnerships

Affiliate Program
Partnerships

Create account

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

First Name

Last Name

Email

Password

I agree with the Terms of Use and Privacy Policy.

Already have an account?

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account

Sign In

Let the news trading begin!

Continue with Google

Continue with Facebook

Continue with Reddit

Continue with Discord

or

Email

Password

Remember me

Lost your password?

Not registered yet?

Create a free account